share_log

博瑞医药(688166.SH):依维莫司原料药获得欧洲CEP证书

Borui Pharmaceutical (688166.SH): Everolimus API obtained European CEP certificate

Gelonghui Finance ·  Feb 19 02:43

Glonghui, Feb. 19: Borui Pharmaceutical (688166.SH) announced that everolimus raw materials have received a CEP (European Pharmacopeia Suitability Certification) certificate issued by the European Medicines Quality Administration (“EDQM”). Everolimus is suitable for adult patients with advanced renal cell carcinoma who have previously received sunitinib or sorafenib treatment failure; adult patients with unresectable, locally advanced (moderately differentiated or highly differentiated) pancreatic neuroendocrine tumors; adult subventricular giant star with tuberous sclerosis (TSC) associated with unresectable, locally advanced or metastatic, well-differentiated, advanced stage non-functional gastrointestinal or pulmonary neuroendocrine tumors (NET) requiring therapeutic intervention but not suitable for surgical resection Plasmacytoma (SEGA) adults and children Patients; adult patients with tuberous sclerosis-related renal vascular leiomyomatosis (TSC-AML) without immediate surgery.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment